Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Nasdaq Real Time Price USD

Verastem, Inc. (VSTM)

Compare
5.70
-0.14
(-2.40%)
At close: April 3 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
10,000
10,000
--
2,596
2,053
Gross Profit
--
--
--
2,596
2,053
Operating Expense
124,956
124,956
92,084
75,533
63,462
Operating Income
-114,956
-114,956
-92,084
-72,937
-61,409
Net Non Operating Interest Income Expense
-413
-413
2,075
-922
-9,791
Other Income Expense
-15,083
-15,083
2,642
47
--
Pretax Income
-130,452
-130,452
-87,367
-73,812
-71,200
Tax Provision
185
185
--
--
--
Net Income Common Stockholders
-130,637
-130,637
-87,367
-73,812
-71,200
Diluted NI Available to Com Stockholders
-130,637
-130,637
-87,367
-73,812
-71,200
Basic EPS
-3.66
-3.66
-3.96
-4.57
-4.92
Diluted EPS
-3.66
-3.66
-3.96
-4.57
-4.92
Basic Average Shares
35,713
35,713
22,054
16,138
14,533.83
Diluted Average Shares
35,713
35,713
22,054
16,138
14,533.83
Total Operating Income as Reported
-114,956
-114,956
-92,084
-72,937
-61,409
Total Expenses
124,956
124,956
92,084
75,533
63,462
Net Income from Continuing & Discontinued Operation
-130,637
-130,637
-87,367
-73,812
-71,200
Normalized Income
-115,509.29
-115,509.29
-87,367
-73,812
-71,200
Interest Income
4,149
4,149
6,214
1,215
181
Interest Expense
4,562
4,562
4,139
2,137
9,972
Net Interest Income
-413
-413
2,075
-922
-9,791
EBIT
-125,890
-125,890
-83,228
-71,675
-61,228
EBITDA
-125,864
-125,864
-83,166
-71,557
-61,156
Reconciled Depreciation
26
26
62
118
72
Net Income from Continuing Operation Net Minority Interest
-130,637
-130,637
-87,367
-73,812
-71,200
Total Unusual Items Excluding Goodwill
-19,149
-19,149
--
--
--
Total Unusual Items
-19,149
-19,149
--
--
--
Normalized EBITDA
-106,715
-106,715
-83,166
-71,557
-61,156
Tax Rate for Calcs
0
0
--
--
--
Tax Effect of Unusual Items
-4,021.29
-4,021.29
--
--
--
12/31/2021 - 1/27/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CRDF Cardiff Oncology, Inc.
2.8700
-4.65%
 
RIGL Rigel Pharmaceuticals, Inc.
17.66
-3.05%
 
KPTI Karyopharm Therapeutics Inc.
3.8600
-4.93%
 
REPL Replimune Group, Inc.
7.89
-8.47%
 
ABEO Abeona Therapeutics Inc.
4.9500
+5.77%
 
IMUX Immunic, Inc.
1.0500
-5.41%
 
KALV KalVista Pharmaceuticals, Inc.
11.32
+2.07%
 
MDGL Madrigal Pharmaceuticals, Inc.
327.10
-2.24%
 
KYMR Kymera Therapeutics, Inc.
23.69
-10.13%
 
EWTX Edgewise Therapeutics, Inc.
13.58
-12.50%